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Summary  This  study  compares  Xpert® HPV  and  Hybrid  Capture® 2  High-Risk  HPV
DNA  TestTM (hc2)  for  the  detection  of  high-risk  HPV  infection  in  cervical  smears.
Papanicolaou  smears  with  atypical  squamous  cells  of  undetermined  signiﬁcance
(ASC-US)  constituted  the  study  specimens.  Of  the  168  ASC-US  samples,  134  (79.8%)ASC-US;
Atypical  squamous
were  from  Saudi  patients.  The  hc2  test  was  positive  in  33  (19.6%)  of  the  total
patients,  20%  among  Saudi  patients,  and  17.6%  among  non-Saudi  patients.  Xpert®
HPV  produced  positive  results  in  30  (17.8%)  of  the  samples.  The  overall  con-cells  of  undeterminedPlease  cite  this  article  in  press  as:  Rabaan  AA,  et  al.  Comparison  of  Xpert® HPV  and  Hybrid  Capture® 2  DNA  TestTM
for  detection  of  high-risk  HPV  infection  in  cervical  atypical  squamous  cells  of  undetermined  signiﬁcance.  J Infect
Public  Health  (2016),  http://dx.doi.org/10.1016/j.jiph.2016.04.017
signiﬁcance cordance  rate  between  the  two  tests  was  98.2%,  and  the  positive  concordance
rate  was  91%.  There  were  three  samples  tested  positive  by  hc2  that  tested  neg-
ative  by  Xpert® HPV.  HPV  16,  HPV  18/45  and  HPV  other  types  were  the  most
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common  types.  Both  tests  have  a  reasonable  positive  concordance  rate,  although  hc2
an  Xpert® HPV.  Xpert® HPV  provides  a  viable  alternative  to
 detection  results  for  samples  with  ASC-US.
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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light was  formed  as  the  chemiluminescent  substrate
was cleaved  by  the  bound  alkaline  phosphatase.
The emitted  light  was  measured  as  relative  light
units (RLUs)  by  a luminometer.  The  light  emitteddetected  more  cases  th
the  hc2  test  with  similar
©  2016  King  Saud  Bin  Ab
Limited.  All  rights  reserv
Introduction
Human  papilloma  virus  (HPV)  infection  may  lead
to persistent  infection  and  is  the  leading  cause  of
cervical cancer.  Genital  HPV  is  a  sexually  transmit-
ted infection  and  almost  all  cervical  cancers  are
caused  by  high  risk  HPV  (hrHPV)  types.  The  risk  of
genital HPV  infection  includes  the  number  of  sex-
ual partners,  new  partner,  older  sex  partner,  use  of
oral contraceptive,  and  condom  use.  HPV  16  and
18 are  the  most  common  hrHPV  and  responsible
for 70%  of  cervical  cancers.  Screening  for  high  risk
HPV (hrHVP)  is  recommended  for  early  detection  of
cervical cancer  [1]. The  U.S.  Food  and  Drug  Admin-
istration (FDA)  approved  four  hrHPV  tests:  Hybrid
Capture® 2 High-Risk  HPV  DNA  TestTM (hc2)  (Qia-
gen, Germantown,  MD;  2003),  Cervista  (Hologic,
Bedford, MA;  2009),  Cobas  HPV  test  (Cobas;  Roche
Molecular  Systems,  Pleasanton,  CA;  2011),  and
Aptima  (Gen-Probe/Hologic,  San  Diego,  CA)  [2].
The hc2  test  detects  hrHPV  types  16,  18,  31,  33,  35,
39, 45,  51,  52,  56,  58,  59  and  68  [2].  The  Cepheid
Xpert® HPV  assay  takes  one  hour  to  complete  and
detects the  same  HPV  high  risk  types  in  addition
to type  66  [2]. A  previous  study  exhibited  similar
detection results  using  Xpert® HPV  and  Cobas  [2].
The hc2  test  has  been  validated  in  large  randomized
trials with  post-examination  follow-up  [3].
The use  of  molecular  detection  of  hrHPV  in
women with  atypical  squamous  cells  of  undeter-
mined signiﬁcance  (ASC-US)  was  shown  to  detect
cancer  and  carcinoma  in  situ  better  than  cytology-
based methods  but  at  a  cost  of  having  lower
speciﬁcity [4]. In  this  study,  we  examined  the  per-
formance  of  Xpert® HPV  and  hc2  tests  in  patients
with ASC-US.  We  also  examined  the  prevalence  of
hrHPV among  women  in  Saudi  Arabia,  where  data
on HPV  is scarce  [5—7].
Materials and methods
Study population and designPlease  cite  this  article  in  press  as:  Rabaan  AA,  et  al.  Compa
for  detection  of  high-risk  HPV  infection  in  cervical  atypical
Public  Health  (2016),  http://dx.doi.org/10.1016/j.jiph.201
The  study  population  included  women  of  all  ages
who were  screened  for  cervical  cancer.  Cervical
i
t
bells  obtained  from  Papanicolaou  (Pap)  smear  spec-
mens were  collected  with  a Cytobrush,  washed
nto PreservCyt  collection  medium  (Hologic,  Inc.,
arlborough,  MA),  and  maintained  at  room  tem-
erature.  At  Johns  Hopkins  Aramco  Healthcare
JHAH), all  samples  were  reviewed  for  integrity
y a cytotechnologist  and  a  pathologist  conﬁrmed
he ﬁnal  diagnosis.  At  JHAH,  only  samples  show-
ng ASC-US  were  referred  for  hrHPV  testing  by  hc2
ssay  (Qiagen,  Gaithersburg,  MD).  These  samples
ere subsequently  tested  by  Xpert® HPV  assay.  Both
ssays were  performed  in  the  molecular  diagnos-
ic laboratory  at  JHAH  between  January  and  July
f 2014.  One  hundred  sixty-eight  Pap  smears  with
SC-US were  submitted  to  the  molecular  diagnostic
aboratory  for  HPV  screening.
he Hybrid Capture® 2 High-Risk HPV DNA
estTM (hc2; Qiagen, Gaithersburg, MD)
he  hc2  test  was  performed  on  all  ASC-US  spec-
mens. Brieﬂy,  4  ml  total  volumes  of  PreservCyt
amples were  processed  using  a  Qiagen  Sample
onversion Kit.  The  kit  prepares  cells  for  hybridiza-
ion in  the  hc2  tests  by  converting  the  PreservCyt
amples into  hc2  compatible  sample  types.  Sam-
les were  then  tested  with  hc2  high  risk  RNA
robes according  to  the  manufacturer’s  recom-
endations [8]. The  hc2  probes  detect  13  high
isk genotypes  as  noted  above.  The  test  was  done
er package  insert  [8]. In  summary,  a speciﬁc
rHPV RNA  probes  hybridize  target  DNA  resulting
n RNA:DNA  hybrids.  These  hybrids  were  then  cap-
ured onto  the  surface  of  a coated  microplate  well
late. A  speciﬁc  alkaline  phosphatase  conjugated
ntibodies for  the  resultant  RNA:DNA,  is  added
nd conjugated  with  a chemiluminescent  substrate
ntibodies.  The  formed  conjugated  antibodies  to
ach captured  hybrid  induce  signal  ampliﬁcation.  Arison  of  Xpert® HPV  and  Hybrid  Capture® 2  DNA  TestTM
 squamous  cells  of  undetermined  signiﬁcance.  J  Infect
6.04.017
ntensity is  relatively  proportion  to  the  amount  of
he target  DNA  in  the  specimen.  A  positive  result  is
ased on  relative  light  units  (RLU)  as  measured  by
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Table  1  Results  of  hc2  and  Xpert® HPV  results  based  on  nationality.
Saudi  (N  =  134),  n  (%) Non-Saudi  (N  =  34),  n  (%) All  (N  =  168),  n  (%)
Hc2  positive* 27  (20)  6  (17.6)  33  (19.6)
Xpert® HPV  Any  Positive* 25  (18.5)  5  (14.7)  30  (17.8)
HPV  16* 6  (4.4)  0  (0)  6  (3.6)
HPV  18/45* 4  (3)  0  (0)  4  (2.3)
HPV  16  and* others*
(coinfection  with  HPV  16
and  other  types)
1 (0.7)  0  (0)  1  (0.6)
HPV  other  types* 14  (10.4) 4  (11.8) 18  (10.7)
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Results
A  total  of  168  ASC-US  samples  were  analyzed  in
this study.  Of  those  samples,  134  (79.8%)  were  from
Saudi patients.  The  mean  age  ±  SD  was  40.6  ±  11.6
years, with  a  range  of  20—83  years.
Xpert® HPV  was  positive  in  30  (17.8%;  95%  CI  of
12.02—23.58) of  the  samples,  whereas  33  (19.6%;
95% CI  of  13.6—25.6)  were  positive  by  hc2.  There
was no  statistically  signiﬁcant  difference  in  HPV-
positivity  between  Saudi  and  non-Saudi  women
(Table  1).  The  most  common  HPV  types  were  HPV
other types  (10.7%),  HPV  16  (3.6%)  and  HPV  18/45
(2.3%). One  patient  had  a  coinfection  with  HPV  16
and other  types  (Table  1).
Table  2  shows  the  overall  concordance  rate
(98.2%; 95%  CI  =  81—100%)  between  the  two  tests
and the  positive  concordance  rate  (91%;  95%
CI = 96—100%)  (p  value  0.08).  Three  specimens
tested positive  for  hrHPV  by  hc2  but  negative  by
Xpert® HPV,  all  of  which  exhibited  carcinoma  in  situ
neoplasms.
Discussion
We  found  high  overall  concordance  and  positive
concordance rates  between  Xpert® HPV  and  Hybrid
Table  2  Concordance  between  the  results  of  hc2  and
Xpert® HPV  results.
hc2  Total
Positive  Negative
Xpert® HPV
Positive  30  0  30
Negative  3  135  138
Total  33  135  168* p Value > 0.05, Fisher’s exact test.
c2  luminometer.  A  specimen  was  considered  pos-
tive if  the  RLU  was  more  than  2.5  in  comparison
o the  average  RLU  of  triplicates  of  a  control  cal-
brator.  If  the  RLU  of  a  sample  was  between  1.0
nd 2.5,  then  the  specimen  was  considered  equivo-
al and  was  repeated.  If  the  repeat  RLU  was  ≥1.0,
he sample  was  considered  positive,  according  to
he manufacturer’s  recommendations.  Three  nega-
ive controls,  one  low  risk  HPV,  one  high  risk  HPV,
nd three  positive  calibrators  were  included  in  each
ssay run.
epheid Xpert® HPV test (Cepheid,
unnyvale, CA, United States)
ll  samples  were  tested  by  Xpert® HPV  assay
imultaneously  with  hc2  assay.  Based  on  the  man-
facturer’s  instructions,  samples  were  shaken  for
everal seconds,  and  1  ml  total  volume  of  Preserv-
yt was  poured  into  an  Xpert® HPV  cartridge  and
ubsequently  loaded  into  Cepheid  Xpert  Diagnosis
nstrument that  uses  a  second  generation  real-time
CR [2].  Interpretation  of  assay  results  followed  the
anufacturer’s  instructions  as  described  previously
2].  This  assay  detects  the  previously  mentioned
3 high  risk  types  and  possibly  HPV  type  66  [2,9].
ssay results  were  reported  as  negative  or  positive
or HPV16,  HPV  18/45,  or  other  HPV  types.  A  Probe
heck Control  and  a  Sample  Adequacy  Control  were
ncluded  in  each  cartridge.
tatistical analysis
he  percentages  of  positive  tests  were  assessed
or signiﬁcance  using  a  Fisher’s  exact  test  to  mea-Please  cite  this  article  in  press  as:  Rabaan  AA,  et  al.  Comparison  of  Xpert® HPV  and  Hybrid  Capture® 2  DNA  TestTM
for  detection  of  high-risk  HPV  infection  in  cervical  atypical  squamous  cells  of  undetermined  signiﬁcance.  J Infect
Public  Health  (2016),  http://dx.doi.org/10.1016/j.jiph.2016.04.017
ure the  difference  between  Saudi  and  non-Saudi
omen. The  McNemar  2 test  was  used  to  assess
igniﬁcance of  discordance.  A  p-value  of  ≤0.05  was
onsidered  to  be  signiﬁcant.
Positive concordance rate 30/33 = 91% (95% CI = 81—100%).
Overall concordance rate 165/168 = 98.2% (95%
CI = 96—100%).
McNemar Chi-square statistic 3.0 (p-value is 0.083).
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Table  3  Summary  of  the  different  studies  from  Saudi  Arabia  of  the  prevalence  of  HPV  among  different  population.
Reference  number Population  Test  used  Number  Number  (%)
positive
Most  common
types
[3]  Histopathologically
proven,  locally
advanced,  cervical
cancer
Linear  Array  HPV
Genotyping  Test
(LA  HPV  GT;
Roche
Diagnostics).
100 82  (82)  HPV-16  (71%);
HPV-31  (7%)
[4]  Parafﬁn-embedded
cervical  tumors
Linear  Array  kit
(Roche
Diagnostic)
100  89  (89)  HPV-16  (65.2%),
31  (7.9%),  45
(6.7%)
[5]  Cervical  cancer
and  carcinoma
in  situ
DNA  sequencing
and  reverse  line
blot  hybridization
assay
90  86  (95.5) HPV-16  (63.4%);
HPV-18  (11.1%),
HPV-45  (4.5%)
Current  study  Atypical  squamous
cells  of
undetermined
signiﬁcance
Xpert® HPV  and
Hc2  Hybrid
Capture® 2  (HC2)
168  Hc2  test:  33
(19.6);  Xpert®
HPV  gave:  30
(17.8)
HPV  16  (3.6);
HPV  18/45  (2.3);
HPV  16  and
other  types  (0.6)
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High concordance  rates  suggest  that  either  test
would be  effective  diagnostics  in  clinical  practice.
In a  previous  study,  the  positive  rate  of  hrHPV  using
Xpert® HPV  was  64.1%  (95%  CI  = 60.4—67.7%)  com-
pared to  58.2%  (95%  CI  = 54.5—61.9%)  when  using
hc2 in  women  referred  for  colposcopy  [2]. The
prevalence of  hrHPV  has  been  determined  as  39.3%
and 45.6%  by  Cobas  Amplicor  and  hc2,  respectively,
with an  overall  agreement  of  89.2%.  [10—12]  in
different populations.  In  this  study,  positive  rates
of hrHVP  were  17.8%  for  Xpert® HPV  compared  to
19.6% for  hc2.  In  previous  studies  of  Saudi  women
with cervical  cancer,  HPV  infection  was  detected  in
89%-95.5%  of  the  cases  [5—7],  and  the  most  common
genotypes were  HPV-16  (63.4%),  HPV-18  (11.1%),
HPV-45  (4.5%),  and  HPV-33  [5]. These  studies  dif-
fer from  ours  in  the  type  of  specimen  used  and
pathology, which  may  give  rise  to  differences  in  the
prevalence  of  HPV  infection  (Table  3).
There  is  discordance  between  hc2  and  Xpert®
HPV  assays.  False-positives  can  arise  from  insufﬁ-
cient denaturation  of  the  cervical  samples  from  PAP
smears in  the  hc2  test  procedure.  Partial  or  incom-
plete  denaturation  of  non-speciﬁc  RNA/DNA  hybrids
that are  present  in  the  cervical  sample  may  cause
a false  positive  result  [11].  False-positives  could
also occur  due  to  contamination  of  the  hc2  HPV
DNA specimen  with  non-speciﬁc  RNA/DNA  hybrids
[11].  It  has  been  shown  that  hc2  probes  cross-reactPlease  cite  this  article  in  press  as:  Rabaan  AA,  et  al.  Compa
for  detection  of  high-risk  HPV  infection  in  cervical  atypical
Public  Health  (2016),  http://dx.doi.org/10.1016/j.jiph.201
with low  risk  HPV-6  and  HPV-42  types  at  concentra-
tions ≥4  ng/ml  [8]. Cross-reactivity  in  the  hc2  assay
may occur  due  to  the  presence  of  bacterial  plasmid
pBR322  in  cervical  samples  [8]  and  the  presence
C
Nf  genetically  similar  HPV  types  [13]. The  reason
or discordance  among  three  samples  in  the  current
tudy  is  not  clear.  The  presence  of  interfering  sub-
tances, such  as  anti-fungal  cream,  contraceptive
el, or  douche,  may  account  for  this  discrepancy.
he difference  in  volume  used  in  both  tests  or  low
PV DNA  copies  in  analyzed  specimens  may  have  an
ffect on  the  detection  of  HPV.
Several HPV-negative  samples  analyzed  by  two
CR assays  have  been  shown  as  positive  by  hc2  [8].
he DNA  sample  used  in  the  PCR  assays  may  not
e representative  of  the  HPV  types  present  in  the
ample  used  in  the  hc2  High-Risk  HPV  DNA  assay
10]. Further  studies  are  needed  to  characterize
he three  Hc2-positive/Xpert® HPV-negative  cases
n this  study  using  alternative  technologies  for  fur-
her evaluation  of  high  risk  targets.  In  conclusion,
pert® HPV  provides  a viable  alternative  to  the  hc2
est with  good  agreement  for  samples  with  ASC-US.
urther  studies  are  needed  to  provide  outcome  data
uch that  sensitivity  and  speciﬁcity  for  underlying
re-cancer (histologically  conﬁrmed  CIN2+)  may  be
erived for  either  assay.
unding
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